A detailed history of Efg Asset Management (Americas) Corp. transactions in Argenx Se stock. As of the latest transaction made, Efg Asset Management (Americas) Corp. holds 371 shares of ARGX stock, worth $233,106. This represents 0.04% of its overall portfolio holdings.

Number of Shares
371
Previous 495 25.05%
Holding current value
$233,106
Previous $212,000 5.19%
% of portfolio
0.04%
Previous 0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$434.22 - $551.9 $53,843 - $68,435
-124 Reduced 25.05%
371 $201,000
Q2 2024

Aug 06, 2024

SELL
$356.01 - $451.55 $9,968 - $12,643
-28 Reduced 5.35%
495 $212,000
Q1 2024

Apr 22, 2024

SELL
$356.95 - $413.29 $47,117 - $54,554
-132 Reduced 20.15%
523 $205,000
Q4 2023

Feb 01, 2024

SELL
$338.91 - $506.01 $69,815 - $104,238
-206 Reduced 23.93%
655 $249,000
Q3 2023

Nov 09, 2023

SELL
$369.35 - $548.43 $36,565 - $54,294
-99 Reduced 10.31%
861 $423,000
Q2 2023

Aug 29, 2023

SELL
$360.14 - $422.58 $36,734 - $43,103
-102 Reduced 9.6%
960 $374,000
Q1 2023

May 04, 2023

SELL
$334.23 - $403.65 $9,692 - $11,705
-29 Reduced 2.66%
1,062 $395,000
Q4 2022

Feb 09, 2023

SELL
$342.17 - $402.31 $46,535 - $54,714
-136 Reduced 11.08%
1,091 $413,000
Q3 2022

Nov 07, 2022

BUY
$343.2 - $395.75 $343 - $395
1 Added 0.08%
1,227 $433,000
Q2 2022

Jul 13, 2022

SELL
$269.58 - $378.88 $103,788 - $145,868
-385 Reduced 23.9%
1,226 $465,000
Q1 2022

May 05, 2022

BUY
$254.45 - $351.06 $5,343 - $7,372
21 Added 1.32%
1,611 $508,000
Q4 2021

Jan 24, 2022

BUY
$272.01 - $353.03 $100,371 - $130,268
369 Added 30.22%
1,590 $557,000
Q3 2021

Oct 22, 2021

BUY
$295.0 - $350.58 $38,940 - $46,276
132 Added 12.12%
1,221 $369,000
Q2 2021

Jul 23, 2021

BUY
$257.11 - $319.92 $279,992 - $348,392
1,089 New
1,089 $328,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.8B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Efg Asset Management (Americas) Corp. Portfolio

Follow Efg Asset Management (Americas) Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (Americas) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (Americas) Corp. with notifications on news.